MedTrace Logo

Impact of Gonadotoxic Therapies on Fertility

NCT05885048 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2024-06-03

No results posted yet for this study

Summary

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.

The main questions it aims to answer are:

* in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve);
* in males, if cancer therapies reduce sperm concentration (sperm quality).

Conditions

  • Cancer
  • Fertility Issues
  • Fertility Preservation
  • Toxicity Due to Chemotherapy
  • Toxicity Due to Radiotherapy
  • Effects of Immunotherapy

Interventions

DIAGNOSTIC_TEST

Blood samples for analysis

Test hormone levels in blood

DIAGNOSTIC_TEST

Sperm samples for analysis

Spermiogram

OTHER

Satisfaction evaluation

Participant satisfaction assessment

OTHER

Quality of Life questionnaire

The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)

Sponsors & Collaborators

  • University of Bern

    collaborator OTHER

  • Michael von Wolff

    lead OTHER

Principal Investigators

  • Michael von Wolff, Prof. Dr. · Insel Gruppe AG, University Hospital Bern

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2028-12-31
Completion
2038-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05885048 on ClinicalTrials.gov